The purpose of this study was to assess the efficacy of continuous renal replacement therapies in patients with severe sepsis or septic shock, with or without acute kidney injury. We performed a systematic search in Medline, Embase, Web of Knowledge, Cochrane Library and Clinicaltrials.gov and a hand search of the retrieved studies. We included both randomised controlled clinical trials and subgroups of randomised trials that assessed the effect of continuous renal replacement therapies (at traditional or high doses) and reported clinical outcomes in adult patients with severe sepsis or septic shock. The study selection and data extraction were performed by duplicate. Analysis of heterogeneity and meta-analysis was performed according to the Cochrane Collaboration guidelines for conducting systematic reviews of interventions.
Severe sepsis and septic shock carry a high mortality and account for a large proportion of patients admitted to intensive care units [1] [2] [3] [4] .
It is widely accepted that the release of large amounts of pro-and anti-inflammatory mediators that occurs in severe sepsis contributes to the development of multiple organ dysfunction syndrome (MODS) [5] [6] [7] [8] , including acute kidney injury (AKI). Theoretically, high-dose continuous renal replacement therapies (CRRT) could remove mediators by convection and/or adsorption 9,10 and reduce mortality, even in the absence of AKI 11 . However, most current clinical practice guidelines suggest that the traditional doses of CRRT used in AKI, with or without sepsis, are insufficient to remove these mediators and recommend using at least 35 ml/kg/hour of ultrafiltration 12, 13 .
Recently, two large randomised clinical trials in patients with AKI (ATN study 14, 15 and RENAL study 16, 17 ) have seriously challenged these recommendations. Additionally, four recent metaanalyses about effectiveness of CRRT in critical patients with AKI [18] [19] [20] [21] have described no impact on the mortality or secondary outcomes of these techniques. The uncertainty regarding the effectiveness of CRRT in patients with sepsis without renal failure is even greater.
The object of this review was to assess the effectiveness of CRRT at high or conventional doses in patients with severe sepsis or septic shock, with or without (AKI).
MATERIALS AND METHODS Inclusion and exclusion criteria
Studies were included in the review if they met the following criteria: 1) design: controlled clinical trials (including randomised controlled trials and subgroups of randomised trials); 2) patients: studies conducted in adults (16 years old or greater) with a diagnosis of severe sepsis or septic shock, with or without acute kidney failure, according to the authors' definition; 3) intervention: studies evaluating continuous veno-venous haemofiltration or haemodiafiltration (at high or standard doses) compared with continuous veno-venous haemofiltration or haemodiafiltration at standard doses or no CRRT; studies in which combined continuous and intermittent therapies were initially included, and their impact assessed with sensitivity analysis; 4) outcomes: studies that measured short-term mortality (hospital mortality or mortality at 15 to 90 days).
Along with mortality (primary endpoint), other clinical outcomes were analysed (secondary endpoints) whenever possible: haemodynamic response (mean arterial pressure or use of vasopressor drugs using an explicit protocol), pulmonary gas exchange (P a O 2 /FiO 2 ratio), incidence and/or evolution of MODS or length of stay in the intensive care unit.
The exclusion criteria were as follows: 1) interventional studies without external control groups (e.g. crossover trials, studies of observed versus expected mortality); 2) studies without sufficient data to assess mortality, 3) studies evaluating other renal replacement therapies (e.g. peritoneal dialysis or coupled plasma filtration immunoadsorption); 4) studies prior to 1995. No a priori language restrictions were established.
The authors of potentially relevant studies were occasionally contacted to clarify the inclusion 22, 23 , but were not used as a primary source of data. The distinction between septic and non-septic patients in three studies [24] [25] [26] was provided by a recent meta-analysis 20 .
Study selection and data extraction
Studies were selected according to the the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines 27 . The retrieved studies were assembled into a bibliographic database. After eliminating duplicates, the articles were subjected to a screening process from the title and abstract to exclude irrelevant studies. We obtained full-text versions of the pertinent articles to determine whether they met inclusion and exclusion criteria. The results of the selection process are summarised in Figure 1 .
The extracted data included the setting of the study, type of patients, renal replacement techniques, clinical outcomes and methodological quality of the studies (Tables 2 to 4). The doses used were classified as traditional (<35 ml/kg/hour), high (35 to 65 ml/kg/hour) or very high (>65 ml/kg/hour).
The methodological quality of studies was assessed according to the recommendations of the Cochrane Collaboration 28 , which considers six domains, coded as 1 (no), 2 (unclear) or 3 (yes): generation of a random list to allocate the study subjects, concealed sequence of randomisation, blinding, attrition and exclusions after randomisation, selective reporting of outcomes and other. The latter domain included the following pre-defined features: study design (primary randomised controlled trial versus sepsis subgroup), early stopping by benefit 29 , misbalanced baseline prognostic variables, under-dosage of haemofiltration (in the control or experimental group), observed versus expected mortality, statistical power (to detect a mortality reduction of 20%) and Jadad's scale 30 .
The screening and selection of articles and data extraction were performed in duplicate, and disagreements were resolved by consensus.
Statistical methods
Due to the clinical heterogeneity of the studies, the effect of haemofiltration on mortality was analysed using a random effects meta-analysis (DerSimonian-Laird 31 ). Statistical heterogeneity was assessed by the Q test, the I 2 statistic 32 and the Galbraith plot 33 . The risk of publication bias and/or small study effect was explored by constructing a funnel plot with enhanced contours 34 and Harbord's test 35 .
Random effects meta-regression was performed by the residual maximum likelihood method 36 . The following pre-selected variables were analysed in the meta-regression model: study design (randomised controlled trial versus randomised trial subgroup), methodological quality of the study (the six domains recommended by the Cochrane Collaboration), renal replacement therapy dose (prescribed or applied), epidemiological design of the study (randomised controlled trial in patients with sepsis versus sepsis subgroup included in a randomised controlled trial), use of renal replacement therapy in the control group, severity of illness (mean Acute Physiology and Chronic Health Evaluation II score in the control group), year of publication and financial support.
Additionally, several exploratory sensitivity analyses were conducted to examine the impact of meta-analysis model (fixed versus random effects), selected association measure (odds ratio vs relative risk) and type of intervention (continuous vs mixed continuous-intermittent techniques).
Given the diversity of measures used, the effects of CRRT on other outcomes (haemodynamics, P a O 2 / FiO 2 , MODS and length of stay) were analysed using a narrative synthesis of the evidence.
The analyses were performed using the software Stata/IC 11.0, Review Manager 5.0.23, StatsDirect 2.7.7, Reference Manager 12 and GPower 3.0.
RESULTS

Included and excluded studies
Initially, 3776 potentially relevant articles were screened for inclusion in the review. We determined that 3741 of these were not relevant after examination of the title or abstract. After full-text review of the remaining 35 articles, eight studies were excluded because they lacked an external control group 37-44 , 10 studies had a control group different from CVVH or no dialysis [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] and five additional studies were excluded due to insufficient raw data to assess mortality using a two-by-two table 22, 23, [55] [56] [57] . Therefore, 12 studies were finally included in the review 8, 9, 14, 16, [24] [25] [26] [58] [59] [60] [61] [62] (Figure 1 , Tables 2 and 3 ). Three of the included studies 8, 58, 62 assessed the effect of CVVH versus no CRRT, while the remaining nine studies 9,14,16,24-26,59-61 assessed the effect of higher versus lower doses. Most of these studies included exclusively patients with AKI 9, 14, 16, [24] [25] [26] 59, 61 . Only three studies included patients without AKI 8, 58, 62 , two of them 8, 58 used low doses of therapy versus standard medical treatment.
Quality of the studies
Whereas all the included studies were described as 'randomised', only six studies described how the random list was generated 8, 14, 16, 25, 26, 62 (Table 4 ). The sequence of allocation was concealed in five studies 8, 14, 16, 25, 26 , and unclear in the remaining seven studies. Due to the nature of the intervention, all of the included studies were non-blinded.
Nine studies were free of significant attrition or exclusions after randomisation 8, 14, 16, [24] [25] [26] 59, 60, 62 . The risk of bias due to exclusions was considered high in two studies 58, 61 . One additional study that reported complete follow-up 9 was found later to have excluded patients with septic shock 63 , so its risk of bias due to exclusion after randomisation was considered unclear. Four studies had study protocol available and were considered free of selective outcome reporting bias 14, 16, 26, 62 . The risk of selective reporting bias was considered high in one study which reported an unusual primary outcome (survival at 15 days after discontinuation of treatment) 9 and unclear in the remainder of the studies. Most of the included studies showed other pre-defined limitations, such as the existence of misbalanced groups [58] [59] [60] [61] , excessive mortality in the control group 9, 60 , under-dosage in the experimental group 8, 26, 58 or early stopping by benefit (Saudan et al 25 
Effect on mortality
There was no evidence of benefit in studies which used renal replacement therapy at traditional doses (less than 35 ml/kg/hour) or high doses (35 to 65 ml/kg/hour) ( Figure 2 ). The relative risk was slightly lower in studies that used more than 65 ml/kg/hour 60, 61 (relative risk=0.84, 95% confidence interval 0.59 to 1.19), however there was no statistical interaction between trial group and dose (P=0.237).
Taken as a whole, the included studies showed a moderate degree of statistical heterogeneity (I 2 =52%, P=0.02) (Figure 2 ) with a pooled risk ratio (random effects) of 0.96 (0.83 to 1.12). The Galbraith plot identified the study of Saudan et al 25 as an outlier. After the exclusion of this study, the heterogeneity was low (I 2 20%, P=0.25) with a pooled risk ratio of 1.0 (0.90 to 1.11). There was no suggestion of publication bias and/or small studies effect in the funnel plot (Figure 3) . These results were robust to the exclusion of the ATN study that used a combination of continuous and intermittent renal replacement therapies 14 .
The univariate meta-regression analysis did not detect significant effect of any of the predefined variables including prescribed or applied dose, type of epidemiological study (randomised controlled trials versus subgroups of randomised trials) or risk of bias (Table 5 ).
Other outcomes
In addition to mortality, several of the randomised studies included in the review assessed other clinical outcomes. However, the heterogeneity of measures used did not allow the conducting of a statistical synthesis.
The haemodynamic effect of haemofiltration was assessed in seven randomised studies 8, 14, [58] [59] [60] [61] [62] . One 61 reported a higher proportion of 'responders' (defined as a decreased noradrenaline dose of more than 75% in 24 hours) in the high volume haemofiltration group (P=0.004). The remaining six studies did not find any systematic benefit of haemofiltration on the haemodynamic parameters or vasopressor support.
Pulmonary function was examined in five randomised studies 16, 24, 59, 61, 62 . No association was detected between haemofiltration and P a O 2 /FiO 2 ratio 59, 61, 62 or duration of mechanical ventilation 16, 24 . Five studies 8, [59] [60] [61] [62] reported the effect of haemofiltration on the evolution of MODS. None showed benefit and one reported a more rapid deterioration of the SOFA scores in the experimental group (P=0.027). Length of stay in the intensive care unit or the hospital was reported in six studies 14, 16, 24, 25, 61, 62 with negative results. The study of Saudan et al 25 reported a tendency (P=0.06) toward a longer intensive care unit stay in the experimental group. Various studies reported adverse effects of the treatment. Payen et al 62 reported a higher incidence and severity of organ failure in the experimental group. The RENAL study 16 reported an increased incidence of hypophosphataemia in the experimental group (P <0.001). The ATN study 14 reported a higher incidence of hypotension requiring vasopressor therapy (P=0.02), hypophosphataemia (P=0.001) and hypokalaemia (P=0.03) in the experimental group.
DISCUSSION
In contrast to the study of Van Wert 20 which included septic patients with AKI, our study tried to respond to the question of effectiveness of CRRT in relevant clinical outcomes in these patients with or without AKI. Our results suggest that the addition of CRRT or its use at high doses does not improve the clinical outcomes of patients with severe sepsis or septic shock with or without AKI and irrespective of the technique used or the definition of AKI. Albeit conventional haemofiltration, haemofiltration using high cut-off filters, high volume haemofiltration and haemodiafiltration are clearly different, the results are consistent and homogeneous, evidencing a lack of effect. With regard to mortality, only one trial 25 reported a significant reduction in mortality. However this was a small study (based on 28 events) 64 , which was stopped early by benefit 28, 29, 65 , which reported an unusual reduction in mortality (risk ratio of 0.31), and that was identified as an outlier in the tree plot ( Figure 2 ) and funnel plot ( Figure 3 ). Therefore, there is a high probability that it was a false positive. After exclusion of this trial, the heterogeneity was greatly reduced and the pooled relative risk was 1.
A specific consideration should be done with respect to three studies comparing conservative treatment versus CVVH or high volume haemofiltration 58, 62 , or in patients without AKI 8 respectively. Although it is doubtful whether these studies should be analysed together due to differences in design, a subgroup analysis did not reveal any subgroup effect.
One concern with our study could be the mixing of different types of renal replacement therapies, specially continuous and intermittent. Only one study 14 included both types of techniques and this issue was specifically addressed in the metaregression analysis. The effect on mortality did not change if this study was included or not, showing that the schedule of application of renal replacement therapies was not a factor capable to modifying our conclusions.
With respect to other outcomes such as improvement in haemodynamic status or pulmonary oxygenation, much of the available evidence comes from animal and non-randomised studies (mainly pre-post studies without external control groups [37] [38] [39] 41 ) not included in this review. However, the evidence based on randomised controlled trials is consistent with that of mortality. Only one study with significant methodological limitations reported a reduction in the use of vasopressors in the experimental group 61 , and none of the trials reviewed reported an improvement in gas exchange, duration of mechanical ventilation, development of MODS or length of stay. Respect to other outcomes, two recent metaanalyses 18, 20 found no effect of high-dose renal replacement therapy on dialysis dependence or length of stay in patients with AKI.
We did not detect any difference of effect of haemofiltration according to the three groups of doses used. However, only two small studies used doses higher than 65 ml/kg/hour. Therefore our study does not preclude the efficacy of these doses in patients with severe sepsis or septic shock. The dose for attaining a sepsis could very likely be different from the dose used for renal support in AKI. Currently there is an ongoing randomised clinical trial 66 addressing this issue. In any case, the results of our review do not support the routine use of doses higher than 35 ml/kg in patients with severe sepsis with or without AKI.
Similarly, this review is limited to studies comparing high-dose haemofiltration-haemodiafiltration or standard haemofiltration-haemodiafiltration versus traditional dosage or no haemofiltration. Thus, the study results cannot be generalised to other haemofiltration techniques with dialysis (e.g. high adsorption filters, filters of high porosity or plasmapheresis).
A further limitation of our study is that six of the 12 studies which met the inclusion criteria were actually not designed to study patients with severe sepsis and septic shock. These studies evaluated patients with AKI and some had very low numbers of septic patients. Furthermore, these groups of septic patients may not have been defined in the same way across studies. Therefore, the external validity of our study is limited by the scarcity of randomised controlled trials addressing specifically clinical outcomes of renal replacement therapies in septic patients. Indeed, almost all the studies that compared high versus low doses were performed in patients with AKI. The effect of high doses in septic patients without acute kidney injury therefore cannot be fully evaluated until well-designed and powered trials are performed.
Finally, the efficacy of haemofiltration in patients with non-infectious systemic inflammatory response syndrome is beyond the scope of this review. It is possible that patients with systemic inflammatoryresponse syndrome (post-cardiac arrest syndrome 67 , severe trauma 68,69 , pancreatitis 23 , severe burns 44 ) experience a massive release of mediators and therefore may benefit from early haemofiltration. In contrast, patients with sepsis undergo haemofiltration at a later stage in the course of the disease. It can be hypothesised that the haemofiltration in patients with sepsis is performed outside the therapeuticwindow when organ damage has already occurred. Further research is needed to address this issue.
